Table 3.
Univariate analysis of progression‐free survival from the initiation of AMR therapy
| Progression‐free survival | |||
|---|---|---|---|
| Variables | Hazard ratio | 95% CI | P‐value |
| Age (≤ 66 vs. ≥ 67 years) | 1.27 | 0.71–2.34 | 0.42 |
| Gender (male vs. female) | 0.97 | 0.51–1.83 | 0.93 |
| PS (0 vs.1,2) | 0.56 | 0.28–0.95 | 0.04 |
| Stage (IIIA, IIIB vs. IV) | 0.53 | 0.28–1.07 | 0.10 |
| EGFR mutation status (mutation vs. wild‐type, unknown) | 2.58 | 0.99–6.76 | 0.053 |
| Histology (adenocarcinoma vs. nonadenocarcinoma) | 1.20 | 0.65–2.27 | 0.56 |
| Smoking status (smoker vs. non‐smoker) | 1.38 | 0.77–2.53 | 0.29 |
| Number of regimens before AMR (<3 vs. ≥ 3) | 0.53 | 0.26–0.87 | 0.02 |
| Response to AMR (PR vs. SD, PD) | 0.29 | 0.17–0.66 | <0.01 |
| topoisomerase‐II (low vs. high) | 0.86 | 0.43–1.65 | 0.63 |
| Ki‐67 labeling index (<20 LI vs. ≥20 LI) | 1.04 | 0.58–1.89 | 0.90 |
AMR, amrubicin; CI, confidence interval; CR, complete response; EGFR, epidermal growth factor receptor; HR, hazard ratio; LI, labeling index; PD, progressive disease; PFS, progression‐free survival; PR, partial response; PS, performance status; SD, stable disease.